GlassScriptPhysician profile
Mathew A Mani
NPI 1972603108
$1,264.45
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $153 · 2021: $965 · 2022: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.28 | 2021 | |
| Janssen Products, LP | $220.58 | 2021 | |
| Viiv Healthcare Company | $205.94 | 2020-2021 | |
| Gilead Sciences, INC. | $197.90 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Janssen Biotech, INC. | $30.64 | 2020-2021 | |
| Lilly USA, LLC | $22.47 | 2021 | |
| Smith+Nephew, INC. | $20.64 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Mani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.